178 related articles for article (PubMed ID: 16361573)
1. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
2. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.
Gu C; Oyama T; Osaki T; Kohno K; Yasumoto K
Anticancer Res; 2001; 21(4A):2357-62. PubMed ID: 11724293
[TBL] [Abstract][Full Text] [Related]
3. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer.
Huang J; Tan PH; Li KB; Matsumoto K; Tsujimoto M; Bay BH
Int J Oncol; 2005 Mar; 26(3):607-13. PubMed ID: 15703814
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression.
Oda Y; Ohishi Y; Basaki Y; Kobayashi H; Hirakawa T; Wake N; Ono M; Nishio K; Kuwano M; Tsuneyoshi M
Cancer Sci; 2007 Jul; 98(7):1020-6. PubMed ID: 17459055
[TBL] [Abstract][Full Text] [Related]
5. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma.
Oda Y; Sakamoto A; Shinohara N; Ohga T; Uchiumi T; Kohno K; Tsuneyoshi M; Kuwano M; Iwamoto Y
Clin Cancer Res; 1998 Sep; 4(9):2273-7. PubMed ID: 9748149
[TBL] [Abstract][Full Text] [Related]
6. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
7. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma.
Yasen M; Kajino K; Kano S; Tobita H; Yamamoto J; Uchiumi T; Kon S; Maeda M; Obulhasim G; Arii S; Hino O
Clin Cancer Res; 2005 Oct; 11(20):7354-61. PubMed ID: 16243807
[TBL] [Abstract][Full Text] [Related]
8. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
[TBL] [Abstract][Full Text] [Related]
9. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.
Mutoh K; Tsukahara S; Mitsuhashi J; Katayama K; Sugimoto Y
Cancer Sci; 2006 Nov; 97(11):1198-204. PubMed ID: 16925584
[TBL] [Abstract][Full Text] [Related]
10. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer.
Yahata H; Kobayashi H; Kamura T; Amada S; Hirakawa T; Kohno K; Kuwano M; Nakano H
J Cancer Res Clin Oncol; 2002 Nov; 128(11):621-6. PubMed ID: 12458343
[TBL] [Abstract][Full Text] [Related]
11. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light.
Ohga T; Koike K; Ono M; Makino Y; Itagaki Y; Tanimoto M; Kuwano M; Kohno K
Cancer Res; 1996 Sep; 56(18):4224-8. PubMed ID: 8797596
[TBL] [Abstract][Full Text] [Related]
12. Involvement of a DNA binding protein, MDR-NF1/YB-1, in human MDR1 gene expression by actinomycin D.
Asakuno K; Kohno K; Uchiumi T; Kubo T; Sato S; Isono M; Kuwano M
Biochem Biophys Res Commun; 1994 Mar; 199(3):1428-35. PubMed ID: 7908518
[TBL] [Abstract][Full Text] [Related]
13. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer.
Shibahara K; Sugio K; Osaki T; Uchiumi T; Maehara Y; Kohno K; Yasumoto K; Sugimachi K; Kuwano M
Clin Cancer Res; 2001 Oct; 7(10):3151-5. PubMed ID: 11595709
[TBL] [Abstract][Full Text] [Related]
14. MDR1 gene expression in primary and advanced breast cancer.
Yang X; Uziely B; Groshen S; Lukas J; Israel V; Russell C; Dunnington G; Formenti S; Muggia F; Press MF
Lab Invest; 1999 Mar; 79(3):271-80. PubMed ID: 10092063
[TBL] [Abstract][Full Text] [Related]
15. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.
Wu J; Lee C; Yokom D; Jiang H; Cheang MC; Yorida E; Turbin D; Berquin IM; Mertens PR; Iftner T; Gilks CB; Dunn SE
Cancer Res; 2006 May; 66(9):4872-9. PubMed ID: 16651443
[TBL] [Abstract][Full Text] [Related]
16. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
17. Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1.
Kaszubiak A; Kupstat A; Müller U; Hausmann R; Holm PS; Lage H
Biochem Biophys Res Commun; 2007 May; 357(1):295-301. PubMed ID: 17418094
[TBL] [Abstract][Full Text] [Related]
18. Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells.
Shareef MM; Brown B; Shajahan S; Sathishkumar S; Arnold SM; Mohiuddin M; Ahmed MM; Spring PM
Mol Cancer Res; 2008 Jan; 6(1):89-98. PubMed ID: 18234965
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
Rincon M; Broadwater G; Harris L; Crocker A; Weaver D; Dressler L; Berry D; Sutton L; Michaelson R; Messino M; Kirshner J; Fleming G; Winer E; Hudis C; Appel S; Norton L; Muss H;
Breast Cancer Res Treat; 2006 Dec; 100(3):301-8. PubMed ID: 16773437
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
